Shahab Asgharzadeh1,2, Araz Marachelian1,2, Judith G Villablanca1,2, Wei Yao Liu1, Rebekah Kennedy1, Richard Sposto1,3, Arlene Naranjo4, Sheena Tenney4, Alice L Yu5,6, M Fevzi Ozkaynak7, Paul M Sondel8, Julie R Park9, Robert C Seeger1,2. 1. Children's Hospital Los Angeles and The Saban Research Institute, Los Angeles, California. 2. Keck School of Medicine, Department of Pediatrics, University of Southern California, Los Angeles, California. 3. Keck School of Medicine, Department of Preventive Medicine, University of Southern California, Los Angeles, California. 4. Children's Oncology Group Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida. 5. Rady Children's Hospital, Department of Pediatrics, University of California San Diego, San Diego, California. 6. Institute of Stem Cell and Translational Cancer Research Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan, Taiwan. 7. New York Medical College, Section of Hematology-Oncology and Bone Marrow Transplantation, Valhalla, New York. 8. University of Wisconsin, Departments of Pediatrics, Human Oncology and Genetics, University of Wisconsin, Madison, Wisconsin. 9. Seattle Children's Hospital, Department of Hematology-Oncology and University of Washington, Seattle, Washington.
Abstract
BACKGROUND: Minimal disease quantification may predict event-free survival (EFS) and overall survival (OS). METHODS: We evaluated mRNA expression of five neuroblastoma-associated genes (NB5 assay) in bone marrows (BM) of patients with newly diagnosed high-risk neuroblastoma who received consistent immunotherapy. mRNA expression of CHGA, DCX, DDC, PHOX2B, and TH genes in BM of 479 patients enrolled on the immunotherapy arm of Children's Oncology Group trials ANBL0032 and ANBL0931 was evaluated using real-time polymerase chain reaction (PCR)-based TaqMan low-density array. Results from end-consolidation and end-therapy were analyzed for association with five-year EFS/OS and patient and tumor characteristics. Tests of statistical significance were two-sided. RESULTS: NB5 assay detected neuroblastoma-related mRNA in 222 of 286 (77.6%) of BMs obtained at end-consolidation and 188 of 304 (61.8%) at end-therapy. Any mRNA level detected in end-therapy BM correlated with significantly worse EFS (57% [49.6%-63.7%] vs 73.0% [63.5%-80.4%]; P = 0.005), but not OS. Analysis limited to patients in complete response at end-therapy still found a significant difference in EFS with detectable versus not detectable NB5 assay results (58.9% [49.5%-67.1%] vs 76.6% [66.1%-84.2%]; P = 0.01). End-consolidation results did not correlate with EFS or OS. Multivariable analysis determined end-therapy NB5 assay BM results (P = 0.02), age at diagnosis (P = 0.002), and preconsolidation response (P = 0.02) were significantly associated with EFS independent of other clinical and biological parameters evaluated, including end-therapy response. CONCLUSIONS: If further validated in additional patient cohorts, the NB5 assay's ability to independently predict EFS from end-therapy could improve patient stratification for novel maintenance therapy trials after current end-therapy to improve outcome.
BACKGROUND: Minimal disease quantification may predict event-free survival (EFS) and overall survival (OS). METHODS: We evaluated mRNA expression of five neuroblastoma-associated genes (NB5 assay) in bone marrows (BM) of patients with newly diagnosed high-risk neuroblastoma who received consistent immunotherapy. mRNA expression of CHGA, DCX, DDC, PHOX2B, and TH genes in BM of 479 patients enrolled on the immunotherapy arm of Children's Oncology Group trials ANBL0032 and ANBL0931 was evaluated using real-time polymerase chain reaction (PCR)-based TaqMan low-density array. Results from end-consolidation and end-therapy were analyzed for association with five-year EFS/OS and patient and tumor characteristics. Tests of statistical significance were two-sided. RESULTS: NB5 assay detected neuroblastoma-related mRNA in 222 of 286 (77.6%) of BMs obtained at end-consolidation and 188 of 304 (61.8%) at end-therapy. Any mRNA level detected in end-therapy BM correlated with significantly worse EFS (57% [49.6%-63.7%] vs 73.0% [63.5%-80.4%]; P = 0.005), but not OS. Analysis limited to patients in complete response at end-therapy still found a significant difference in EFS with detectable versus not detectable NB5 assay results (58.9% [49.5%-67.1%] vs 76.6% [66.1%-84.2%]; P = 0.01). End-consolidation results did not correlate with EFS or OS. Multivariable analysis determined end-therapy NB5 assay BM results (P = 0.02), age at diagnosis (P = 0.002), and preconsolidation response (P = 0.02) were significantly associated with EFS independent of other clinical and biological parameters evaluated, including end-therapy response. CONCLUSIONS: If further validated in additional patient cohorts, the NB5 assay's ability to independently predict EFS from end-therapy could improve patient stratification for novel maintenance therapy trials after current end-therapy to improve outcome.
Authors: Yania Yáñez; David Hervás; Elena Grau; Silvestre Oltra; Gema Pérez; Sarai Palanca; Mar Bermúdez; Catalina Márquez; Adela Cañete; Victoria Castel Journal: J Cancer Res Clin Oncol Date: 2015-10-24 Impact factor: 4.553
Authors: Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel Journal: N Engl J Med Date: 2010-09-30 Impact factor: 91.245
Authors: Wayne L Furman; Sara M Federico; Mary Beth McCarville; Barry L Shulkin; Andrew M Davidoff; Matthew J Krasin; Natasha Sahr; April Sykes; Jianrong Wu; Rachel C Brennan; Michael William Bishop; Sara Helmig; Elizabeth Stewart; Fariba Navid; Brandon Triplett; Victor M Santana; Armita Bahrami; Gwendolyn Anthony; Alice L Yu; Jacquelyn Hank; Stephen D Gillies; Paul M Sondel; Wing H Leung; Alberto S Pappo Journal: Clin Cancer Res Date: 2019-10-10 Impact factor: 12.531
Authors: Julie R Park; Susan G Kreissman; Wendy B London; Arlene Naranjo; Susan Lerner Cohn; Michael D Hogarty; Sheena C Tenney; Daphne Haas-Kogan; Peter John Shaw; Jacqueline M Kraveka; Stephen S Roberts; James Duncan Geiger; John J Doski; Stephan D Voss; John M Maris; Stephan A Grupp; Lisa Diller Journal: JAMA Date: 2019-08-27 Impact factor: 56.272
Authors: Gregory A Yanik; Marguerite T Parisi; Barry L Shulkin; Arlene Naranjo; Susan G Kreissman; Wendy B London; Judith G Villablanca; John M Maris; Julie R Park; Susan L Cohn; Patrick McGrady; Katherine K Matthay Journal: J Nucl Med Date: 2013-02-25 Impact factor: 10.057
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: Julie R Park; Judith G Villablanca; Wendy B London; Robert B Gerbing; Daphne Haas-Kogan; E Stanton Adkins; Edward F Attiyeh; John M Maris; Robert C Seeger; C Patrick Reynolds; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2009-01 Impact factor: 3.167